NaviFUS® was approved for an upcoming trial investigating the synergy of focused ultrasound treatment with radiotherapy in patients with end-stage primary brain tumors.
Low radiotherapy doses may yield high-dose therapeutic effects and significantly reduce serious side effects attributed to high-dose radiotherapy.
NaviFUS believes this treatment can also be extended to metastatic brain tumors from lung cancer, breast cancer, etc. The market potential for this treatment is expected to be more than $2 billion US dollars.
NaviFUS announced that it recently made its first overseas sale with its FUS System for Pre-Clinical Research. While the NaviFUS System is currently still in the process of acquiring pre-market approval, a modified version strictly for research purposes can be sold to academic and medical institutions, providing an alternative source of income to NaviFUS.
The clinical results from Taiwan-based NaviFUS’ first phase I clinical trial to open the blood-brain barrier (BBB) in patients with glioblastoma has been published in the journal Science Advances. In “Neuronavigation-Guided Focused Ultrasound for Transcranial Blood-Brain Barrier Opening and Immunostimulation in Brain Tumors,” researchers enrolled six patients with recurrent glioblastoma who were scheduled to undergo surgical resection.
“This is an important study to show the breadth and depth of worldwide research that is currently underway using focused ultrasound to treat these deadly brain tumors,” said Foundation Chairman Neal F. Kassell, MD. “We congratulate the authors and NaviFUS for developing this novel, safe, and innovative way to use the technology.”…
